Original Article

Expressions of CD23, IL-17 and MMP-9 in Patients with Colorectal Cancer


Background: We aimed to detect IL-17, MMP-9 and CD23 in serum of patients with colorectal cancer to provide some proper references for diagnosis and treatment of this disease.

Methods: Overall, 287 patients with colorectal cancer were collected in the Digestive Surgery Department of Chinese PLA General Hospital, Beijing, China from January 2017 to November 2018 and were used as the study group, meanwhile, 200 people who took physical examination in the same period were used as the control group. They were retrospectively analyzed. The concentrations of IL-17, MMP-9 and CD23 in serum were detected by ELISA 10 d before and after treatment and 30 d after treatment. The relationship between IL-17, MMP-9 and CD23 concentration and clinicopathology was analyzed.

Results: The concentrations of CD23, IL-17 and MMP-9 in peripheral blood of the patients in the study group were significantly higher than those in the control group (P<0.001). IL-17, MMP-9 and CD23 were negatively correlated with treatment time and pathological features in the study group (P<0.001).

Conclusion: The concentrations of IL-17, MMP-9 and CD23 obviously increased in peripheral blood of patients with colorectal cancer, the three were negatively correlated with treatment time and were significantly correlated with TNM staging and differentiation degree of colorectal cancer. It is expected to estimate the illness.

1. Bibbins-Domingo K, Grossman DC, Curry SJ et al (2008). Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 149: 627-637.
2. Keegan TH, Ries LA, Barr RD et al (2016). Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer, 122: 1009-1016.
3. Torre LA, Siegel RL, Ward EM, Jemal A (2016). Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev, 25: 16-27.
4. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017). Global patterns and trends in colorectal cancer incidence and mortality. Gut, 66: 683-691.
5. Miller KD, Siegel RL, Lin CC et al (2016). Cancer treatment and survivorship statis-tics, 2016. CA Cancer J Clin, 66: 271-289.
6. Seligmann JF, Fisher D, Smith CG, et al (2017). Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol, 28: 562-568.
7. Venook AP, Niedzwiecki D, Lenz HJ et al (2017). Effect of First-Line Chemothera-py Combined With Cetuximab or Bevaci-zumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Random-ized Clinical Trial. JAMA, 317: 2392-2401.
8. Vafadari B, Salamian A, Kaczmarek L (2016). MMP-9 in translation: from mol-ecule to brain physiology, pathology, and therapy. J Neurochem, 139 Suppl 2: 91-114.
9. Burlaka AP, Ganusevich, II, Gafurov MR, Lukin SM, Sidorik EP (2016). Stomach Cancer: Interconnection between the Re-dox State, Activity of MMP-2, MMP-9 and Stage of Tumor Growth. Cancer Mi-croenviron, 9: 27-32.
10. Lawicki S, Zajkowska M, Glazewska EK, Bedkowska GE, Szmitkowski M (2016). Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the di-agnosis of patients with breast cancer. Onco Targets Ther, 9: 911-919.
11. Papotto PH, Ribot JC and Silva-Santos B (2017). IL-17(+) gammadelta T cells as kick-starters of inflammation. Nat Immu-nol, 18: 604-611.
12. Wang K, Karin M (2015). The IL-23 to IL-17 cascade inflammation-related cancers. Clin Exp Rheumatol, 33: S87-90.
13. Selb R, Eckl-Dorna J, Neunkirchner A et al (2017). CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. J Al-lergy Clin Immunol, 139: 290-299.e294.
14. Raphael J, Valent A, Hanna C et al (2014). Myeloid sarcoma of the nasopharynx mimicking an aggressive lymphoma. Head Neck Pathol, 8: 234-238.
15. Amin MB, Greene FL, Edge SB et al (2017). The Eighth Edition AJCC Cancer Stag-ing Manual: Continuing to build a bridge from a population-based to a more "per-sonalized" approach to cancer staging. CA Cancer J Clin, 67: 93-99.
16. Otsuki T, Matsuzaki H, Lee S et al (2016). Environmental factors and human health: fibrous and particulate substance-induced immunological disorders and construction of a health-promoting living environment. Environ Health Prev Med, 21: 71-81.
17. Derakhshan MH, Arnold M, Brewster DH et al (2016). Worldwide Inverse Associa-tion between Gastric Cancer and Esoph-ageal Adenocarcinoma Suggesting a Common Environmental Factor Exert-ing Opposing Effects. Am J Gastroenterol, 111: 228-239.
18. Bishehsari F, Mahdavinia M, Vacca M, Ma-lekzadeh R, Mariani-Costantini R (2014). Epidemiological transition of colorectal cancer in developing countries: environ-mental factors, molecular pathways, and opportunities for prevention. World J Gas-troenterol, 20: 6055-6072.
19. Drewes JL, Housseau F, Sears CL (2016). Sporadic colorectal cancer: microbial con-tributors to disease prevention, develop-ment and therapy. Br J Cancer, 115: 273-280.
20. Xie H, Ren X, Xin S et al (2016). Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. Oncotarget, 7: 26680-26691.
21. Mir R, Pradhan SJ, Patil P, Mulherkar R, Galande S (2016). Wnt/beta-catenin sig-naling regulated SATB1 promotes colo-rectal cancer tumorigenesis and progres-sion. Oncogene,35(13):1679-91.
22. Zhao L, Yu H, Yi S et al (2016). The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget, 7: 45370-45384.
23. Kathania M, Khare P, Zeng M et al (2016). Itch inhibits IL-17-mediated colon in-flammation and tumorigenesis by ROR-gammat ubiquitination. Nat Immunol, 17: 997-1004.
24. Gong L, Wu D, Zou J et al (2016). Prognos-tic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget, 7: 18458-18468.
25. Lopez-Matas M, Rodriguez-Justo M, Morilla R, Catovsky D, Matutes E (2000). Quan-titative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia. Haematologica, 85: 1140-1145.
26. Wu X, Yang T, Liu X et al (2016). IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer. Tumour Biol, 37: 5493-5501.
27. Zhang Q, Liu S, Parajuli KR et al (2017). In-terleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene, 36: 687-699.
28. Gao YW, Xu M, Xu Y, Li D, Zhou S (2015). Effect of three common IL-17 single nucleotide polymorphisms on the risk of developing gastric cancer. Oncol Lett, 9: 1398-1402.
29. Gaffen SL, Jain R, Garg AV, Cua DJ (2014). The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol, 14: 585-600.
30. Jablonska-Trypuc A, Matejczyk M, Rosochacki S (2016). Matrix metallopro-teinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen deg-radation, as a target for anticancer drugs. J Enzyme Inhib Med Chem, 31: 177-183.
31. Yildiz B, Cetin N, Kural N, Colak O (2013). CD19 + CD23+ B cells, CD4 + CD25+ T cells, E-selectin and interleukin-12 lev-els in children with steroid sensitive ne-phrotic syndrome. Ital J Pediatr, 39: 42.
IssueVol 49 No 2 (2020) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v49i2.3088
Clinicopathology; Colorectal cancer; Interleukin-17

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
GUO X, LIU G, XIE X, LI J, HOU Z, GU Y, YU L. Expressions of CD23, IL-17 and MMP-9 in Patients with Colorectal Cancer. Iran J Public Health. 2020;49(2):257-266.